Hostname: page-component-cd9895bd7-8ctnn Total loading time: 0 Render date: 2024-12-26T08:34:43.617Z Has data issue: false hasContentIssue false
  • English
  • Français

Rivastigmine in the Treatment of Dementia Associated with Parkinson's Disease: A Randomized, Double-blind, Placebo-controlled Study

Published online by Cambridge University Press:  15 February 2006

Sibel Tekin  and
Roger Lane
Sibel Tekin
Affiliation:
Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA; Email: sibel.tekin@novartis.com; roger.lane@novartis.com
Roger Lane
Affiliation:
Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA; Email: sibel.tekin@novartis.com; roger.lane@novartis.com
Get access Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'

Keywords

Parkinson's diseaseclinical trialrivastigmineexecutive functioncholinesterase inhibitordementia
Type
Review Article
Information
Progress in Neurotherapeutics and Neuropsychopharmacology , Volume 1 , Issue 1 , January 2006 , pp. 13 - 25
Copyright
© 2006 Cambridge University Press

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

American Psychiatric Association. (1994). Diagnostic and Statistical Manual of Mental Disorders, 4th edn. Washington DC: American Psychiatric Association.
Anand, R., Messina, J., & Hartman, R. (2000). Dose-response effect of rivastigmine in the treatment of Alzheimer's disease. International Journal of Geriatrics Psychopharmacology, 2, 68–72.Google Scholar
Apaydin, H., Ahlskog, J.E., Parisi, J.E., Boeve, B.F., & Dickson, D.W. (2002). Parkinson disease neuropathology: later-developing dementia and loss of the levodopa response. Archives of Neurology, 59, 102–112.Google Scholar
Bohnen, N.I., Kaufer, D.I., Ivanco, L.S., et al. (2003). Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study. Archives of Neurology, 60, 1745–1748.Google Scholar
Braak, H., Rub, U., Jansen Steur, E.N., Del Tredici, K., & de Vos, R.A. (2005). Cognitive status correlates with neuropathologic stage in Parkinson disease. Neurology, 64, 1404–1410.Google Scholar
Bryant, J., Clegg, A., Nicholson, T., et al. (2001). Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimer's disease: a rapid and systematic review. Health Technology Assessments, 5, 1–137.Google Scholar
Bullock, R., & Cameron, A. (2002). Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson's disease. Current Medical Research and Opinion, 18, 258–264.Google Scholar
Corey-Bloom, J., Anand, R., & Veach, J. (1998). A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. International Journal of Geriatrics Psychopharmacology, 1, 55–65.Google Scholar
Cummings, J.L. (1988). Intellectual impairment in Parkinson's disease: clinical, pathologic, and biochemical correlates. Journal of Geriatric Psychiatry Neurology, 1, 24–36.Google Scholar
Cummings, J.L., Mega, M., Gray, K., et al. (1994). The neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia. Neurology, 44, 2308–2314.Google Scholar
Delis, D.C., Kaplan, E., & Kramer, J.H. (2001). Delis–Kaplan Executive Function System. Texas: Psychological Corporation.Google Scholar
Doody, R.S., Stevens, J.C., Beck, C., et al. (2001). Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology, 56, 1154–1166.Google Scholar
Emre, M. (2003). Dementia associated with Parkinson's disease. Lancet Neurology, 3, 229–237.Google Scholar
Emre, M., Aarsland, D., Albanese, A., et al. (2004). Rivastigmine for the dementia associated with Parkinson's disease. New England Journal of Medicine, 351, 29–38.Google Scholar
Enz, A., & Bodekke, H. (1991). Pharmacologic and clinicopharmacologic properties of SDZ ENA 713, a centrally selective acetylcholinesterase inhibitor. Annals of the New York Academy of Sciences, 640, 272–275.Google Scholar
Enz, A., Amstutz, R., Boddeke, H., Gmelin, G., & Malanowski, J. (1993). Brain selective inhibition of acetylcholinesterase: a novel approach to therapy for Alzheimer's disease. Progress in Brain Research, 98, 431–438.Google Scholar
Esiri, M.M., & McShane, R.H. (1997). In: Esiri, M.M. Morris, J.H. (eds.), The Neuropathology of Dementia. Cambridge, UK: Cambridge University Press.
Fahn, S., Elton, R.L., & Members of the UPDRS development committee. (1987). Unified Parkinson's disease rating scale. In: Fahn, S., Marsden, C.D., Calne, D.B., Goldstein, M. (eds.), Recent Developments in Parkinson's Disease. Florham Park, NJ: MacMillan Healthcare Information, pp. 153–164.
Fogelson, N., Kogan, E., Korczyn, A.D., et al. (2003). Effects of rivastigmine on the quantitative EEG in demented Parkinsonian patients. Acta Neurological Scandinavica, 107, 252–255.Google Scholar
Folstein, M.F., Folstein, F.E., & McHugh, P.R. (1975). “Mini-mental” state. A practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research, 12, 189–198.Google Scholar
Galasko, D., Bennett, D., Sano, M., et al. (1997). An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Alzheimer Disease and Associated Disorders, 11 (Suppl. 2), S33–S39.Google Scholar
Geula, C., Eskander, M., Atkinson, L., et al. (2004). Rivastigmine is a potent inhibitor of cholinesterases in plaques and tangles. Poster presented at the American Psychiatric Association Annual Meeting, New York, 1–6 May 2004.Google Scholar
Gibb, W.R., & Lees, A.J. (1988). The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. Journal of Neurology Neurosurgery and Psychiatry, 51, 745–752.Google Scholar
Grace, J., Daniel, S., Stevens, T., et al. (2001). Long-term use of rivastigmine in patients with dementia with Lewy bodies: an open-label trial. International Psychogeriatrics, 13, 199–205.Google Scholar
Jellinger, K.A. (2004). Lewy body-related alpha-synucleinopathy in the aged human brain. Journal of Neural Transmission, 111, 1219–1235.Google Scholar
Kraybill, M.L., Larson, E.B., Tsuang, D.W., et al. (2005). Cognitive differences in dementia patients with autopsy-verified AD, Lewy body pathology, or both. Neurology, 64, 2069–2073.Google Scholar
Loos, C., Wenig, M., & Steinwachs, C. (2002). Rivastigmine is effective and well tolerated in the treatment of parkinsonian psychosis of geriatric patients. Poster presented at the 6th Congress of the European Federation of Neurological Sciences, Vienna, Austria, 26–29 October 2002.Google Scholar
Manos, P.J., & Wu, R. (1994). The ten point clock test: a quick screen and grading method for cognitive impairment in medical and surgical patients. International Journal of Psychiatry in Medicine, 24, 229–244.Google Scholar
McKeith, I., Del Ser, T., Spano, P.-F., et al. (2000). Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double blind, placebo-controlled international study. Lancet, 356, 2031–2036.Google Scholar
McKeith, I.G., Wesnes, K.A., Perry, E., & Ferrara, R. (2004a). Hallucinations predict attentional improvements with rivastigmine in dementia with Lewy bodies. Dementia and Geriatric Cognitive Disorders, 18, 94–100.Google Scholar
McKeith, I., Mintzer, J., Aarsland, D., et al. (2004b). Dementia with Lewy bodies. Lancet Neurology, 3, 19–28.Google Scholar
Perry, E.K., Curtis, M., Dick, D.J., et al. (1985). Cholinergic correlates of cognitive impairment in Parkinson's disease: comparison with Alzheimer's disease. Journal of Neurology Neurosurgery and Psychiatry, 48, 413–421.Google Scholar
Poewe, W., Wolters, E., Emre, M., et al. (2005). Long-term benefits of rivastigmine in dementia associated with Parkinson's disease: an active treatment extension study. Movement disorders, 14 October, published online (Google: Journal of movement disorders).Google Scholar
Reading, P.J., Luce, A.K., & McKeith, I.G. (2001). Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial. Movement Disorders, 16, 1171–1195.Google Scholar
Rosen, W.G., Mohs, R.C., & Davis, K.L. (1984). A new rating scale for Alzheimer's disease. American Journal of Psychiatry, 141, 1356–1364.Google Scholar
Rosenstein, L.D. (1998). Differential diagnosis of the major progressive dementias and depression in middle and late adulthood: a summary of the literature of the early 1990s. Neuropsychology Review, 8, 109–167.Google Scholar
Rösler, M., Anand, R., Cicin-Sain, A., et al. (1999). Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. British Medical Journal, 318, 633–640.Google Scholar
Schneider, L.S., Olin, J.T., Doody, R.S., et al. (1997). Validity and reliability of the Alzheimer's disease cooperative study – clinical global impression of Change. The Alzheimer's Disease Cooperative Study. Alzheimer Disease and Associated Disorders, 11 (Suppl. 2), S22–S32.Google Scholar
Simpson, P.M., Surmon, D.J., Wesnes, K.A., & Wilcock, G.K. (1991). The cognitive drug research computerized assessment system for demented patients: a validation study. International Journal of Geriatric Psychiatry, 6, 95–102.Google Scholar
Tiraboschi, P., Hansen, L.A., Alford, M., et al. (2000). Cholinergic dysfunction in diseases with Lewy bodies. Neurology, 54, 407–411.Google Scholar
Van Laar, T., de Vries, J.J., Nakhosteen, A., & Leenders, K.L. (2001). Rivastigmine is effective and safe as anti-psychotic treatment in patients with Parkinson's disease. Poster presented at the 13th International Congress on Parkinson's Disease, Helsinki, Finland, July 2001.Google Scholar
Wesnes, K., McKeith, I.G., Ferrara, R., et al. (2002). Effects of rivastigmine on cognitive function in dementia with Lewy bodies: a randomised placebo-controlled international study using the cognitive drug research computerised assessment system. Dementia and Geriatric Cognitive Disorders, 13, 183–192.Google Scholar
Wesnes, K.A., McKeith, I., Edgar, C., et al. (2005). Benefits of rivastigmine on attention in dementia associated with PD. Neurology, 65: 1654–1656.Google Scholar